We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Global X China Biotech Innovations ETF | NASDAQ:CHB | NASDAQ | Exchange Traded Fund |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.64 | 2.67 | 10.66 | 0 | 00:00:00 |
RNS Number:5178O United Technologies Corporation 11 August 2003 Not for release, publication or distribution in, into or from Australia, Canada or Japan 11 August 2003 United Technologies Corporation Recommended Cash Offer for Chubb plc Compulsory Acquisition of Outstanding Chubb Shares United Technologies Corporation ("UTC") announces, in relation to the recommended cash offer (the "Offer") made by a wholly-owned subsidiary of UTC (the "Offeror") and (outside the United States) by UBS Investment Bank and JPMorgan on its behalf for the entire issued and to be issued share capital of Chubb plc ("Chubb"), as set out in the offer document dated 18 June 2003 (the "Offer Document"), that the Offeror has, as of 1pm on 6 August 2003, acquired or agreed to acquire, or received valid acceptances under the Offer in respect of more than 90 per cent. of the Chubb Shares to which the Offer relates and will shortly implement the procedures set out in sections 428 to 430F of the Companies Act to acquire compulsorily those Chubb Shares for which it has not already received acceptances of the Offer. Enquiries: UBS Investment Bank Leanne Gordon-Kagan Tel: +44 20 7567 8000 JPMorgan Edward Banks Tel: +44 20 7777 2000 Computershare Investor Services Tel: 0870 703 0147 (receiving agent) (or +44 870 703 0147 if outside the UK) Unless the context otherwise requires, defined terms used in this announcement shall have the meanings given to them in the Offer Document. This announcement does not constitute an offer to sell or an invitation to purchase any securities or the solicitation of an offer to buy any securities, pursuant to the Offer or otherwise. The full terms and conditions of the Offer (including details of how the Offer may be accepted) are set out in the Offer Document and the Form of Acceptance. The availability of the Offer to Chubb Shareholders who are not resident in and citizens of the United Kingdom or the United States may be affected by the laws of the relevant jurisdictions in which they are located or of which they are citizens. Such persons should inform themselves of, and observe, any applicable legal or regulatory requirements of their jurisdictions. Unless otherwise determined by UTC, the Offer is not being made, directly or indirectly, in or into Australia, Canada, Japan or any jurisdiction where to do so would constitute a breach of securities law in that jurisdiction, and the Offer is not capable of acceptance from or within Australia, Canada, Japan or any such other jurisdiction. Accordingly, copies of this announcement and any related documents are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from Australia, Canada, Japan or any jurisdiction where to do so would constitute a breach of securities laws in that jurisdiction, and persons receiving this announcement (including custodians, nominees and trustees) must not mail or otherwise distribute or send it in, into or from such jurisdictions as doing so may invalidate any purported acceptance of the Offer. Each of UBS Limited ("UBS Investment Bank") and J.P. Morgan plc ("JPMorgan") is acting for UTC and the Offeror and no one else in connection with the Offer and will not be responsible to anyone other than UTC and the Offeror for providing the protections offered to clients respectively of UBS Investment Bank and JPMorgan (as the case may be) nor for providing advice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange END CASGUUCARUPWGQU
1 Year Global X China Biotech I... Chart |
1 Month Global X China Biotech I... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions